Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2012 2
2013 3
2014 1
2015 3
2016 3
2017 3
2019 4
2020 8
2021 9
2022 7
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, Arkenau T, Baird RD, Jeselsohn R, Ali S, Clack G, Bahl A, McIntosh S, Krebs MG. Coombes RC, et al. Among authors: chalasani p. Nat Commun. 2023 Jul 24;14(1):4444. doi: 10.1038/s41467-023-40061-y. Nat Commun. 2023. PMID: 37488191 Free PMC article. Clinical Trial.
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.
Meric-Bernstam F, Calvo E, Lee KS, Moreno V, Park YH, Rha SY, Chalasani P, Zhong W, Zhou L, Pirie-Shepherd S, Leung ACF, Curigliano G. Meric-Bernstam F, et al. Among authors: chalasani p. Mol Cancer Ther. 2023 Oct 2;22(10):1191-1203. doi: 10.1158/1535-7163.MCT-23-0101. Mol Cancer Ther. 2023. PMID: 37420274 Free PMC article. Clinical Trial.
Spontaneous Paraesophageal Hematoma.
Yan J, Walker C, Chalasani P. Yan J, et al. Among authors: chalasani p. ACG Case Rep J. 2015 Oct 9;3(1):29-30. doi: 10.14309/crj.2015.91. eCollection 2015 Oct. ACG Case Rep J. 2015. PMID: 26504872 Free PMC article.
Transcranial Magnetic Stimulation for the Treatment of Chemo Brain.
Kuo PH, Chen AY, Rodriguez RJ, Stuehm C, Chalasani P, Chen NK, Chou YH. Kuo PH, et al. Among authors: chalasani p. Sensors (Basel). 2023 Sep 22;23(19):8017. doi: 10.3390/s23198017. Sensors (Basel). 2023. PMID: 37836847 Free PMC article. Clinical Trial.
Nuclear epidermal growth factor receptor as a therapeutic target.
Atwell B, Chalasani P, Schroeder J. Atwell B, et al. Among authors: chalasani p. Explor Target Antitumor Ther. 2023;4(4):616-629. doi: 10.37349/etat.2023.00156. Epub 2023 Aug 30. Explor Target Antitumor Ther. 2023. PMID: 37720348 Free PMC article. Review.
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.
Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Parris H, Gao D, McSpadden T, Mayordomo J, Diamond JR, Kabos P, Borges VF. Shagisultanova E, et al. Among authors: chalasani p. Clin Cancer Res. 2023 Dec 15;29(24):5021-5030. doi: 10.1158/1078-0432.CCR-23-0117. Clin Cancer Res. 2023. PMID: 37363965 Free PMC article.
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, Arkenau T, Baird RD, Jeselsohn R, Ali S, Clack G, Bahl A, McIntosh S, Krebs MG. Coombes RC, et al. Among authors: chalasani p. Nat Commun. 2023 Aug 7;14(1):4741. doi: 10.1038/s41467-023-40561-x. Nat Commun. 2023. PMID: 37550302 Free PMC article. No abstract available.
50 results